CCTV News:As the Spring Festival approaches, the annual flavor of Foshan, Guangdong Province is getting stronger and stronger. Visiting the flower market, hanging Spring Festival couplets and preparing new year’s goods are filled with festive atmosphere everywhere. What customs are still preserved in Foshan for the New Year? Let’s follow the reporter’s lens and have a look.

The flowers in the Bay Area are in full bloom, celebrating the New Year in Guangdong. Cantonese people pay attention to walking the flower street and buying flowers for the New Year, in order to make a good fortune. Today (January 29), we came to Chencun, Shunde, Foshan, which is located in the hinterland of Guangfu culture in the Pearl River Delta and has a history of planting flowers for more than 2,000 years.

The Qing Dynasty’s "Shunde County Records" recorded that "Chencun sold flowers and fruits to various counties, and offered longan, lychee and Song Gongyi flowers since the Han Dynasty, which has a long history". In this Millennium Flower Town, 9 pots of oranges for every 10 pots sold in China come from here, and there are more than 100 enterprises that cultivate Phalaenopsis, accounting for 30% of the national trading volume.　　

Mandarin orange and Phalaenopsis are also the annual flowers that Cantonese people must buy for the New Year. Four-season orange represents four seasons of good luck, and the beautiful Phalaenopsis, its flower language is "happiness comes to you." In Chencun, Phalaenopsis not only has this traditional pink color, but also has this newly cultivated Phalaenopsis from macaroon, which is very popular among young people.

Now, more than 2,400 varieties of Phalaenopsis have been cultivated here, and not only that, but also Phalaenopsis blooms in all seasons. Although the offline flower market was cancelled this year, everyone can still pass "Yunshang flower market"to achieve," flowers on the cloud "and" flowers on the cloud ". At present, the shipment of annual orange flowers has exceeded 80%, the sales momentum is good, and the price has increased by nearly 20% compared with last year.

In addition to buying New Year’s flowers, there must be lion awakening in Lingnan on holidays. Guangdong lion is one of the national intangible cultural heritages. Every step of the lion’s head binding is made by hand, with bamboo as the bone, paper as the skin, ink as the charm, and fluff as the power. After more than 1300 processes for about a week, a lifelike lion’s head appeared before our eyes.　 　 　 　　

However, there is an important last step before it becomes a dancing lion: the finishing touch.

Wake up the lion and "pick the green", and this lettuce is picked. Lettuce is homophonic for "making money". The lion picked the green, and then distributed it to the neighborhood, indicating that he distributed wealth and blessings to everyone. Here, we also wish the audience good health and great success together.

April Day in Spring, National Science Foundation, USA（NSF）But there was a cold snap-the research funds for the new year were frozen.

Trump Administration Efficiency Department led by American entrepreneur and billionaire elon musk.（DOGE）The reason for this is to cut government spending and reduce staff. According to the latest report in Nature magazine, DOGE is reviewing the list of related research grants evaluated by NSF in February, and considering terminating more than 200 of them.

It’s not just NSF that is bleak. National institutes of health（NIH）Because of the lack of funds, some laboratories can’t even afford gloves, Petri dishes and reagents. National Oceanic and Atmospheric Administration（NOAA）, the US Food and Drug Administration（FDA）, U.S. Environmental Protection Agency（EPA）Scientists in other institutions are also facing the risk of "cooking without rice" and even being fired, and their morale is low and their work is paralyzed.

Many American scientists complain bitterly and bluntly say "feel helpless" and "the future is scary".

First, suffocating censorship

NSF, with a research budget of 9 billion dollars, is one of the largest funding institutions for basic research in the world.

However, since Trump took office as president of the United States this year, the agency has suffered a cold reception one after another: first, all funding was frozen; After that, I received a court unfreezing order in February, but I had to dismiss a large number of probation employees; At the beginning of April, the institution cut the postgraduate scholarship program by half, offering only 1,000 places instead of 2,000 in previous years.

In fact, the Republican Party of the United States has long been "disgusted" with the NSF funding method of the Democratic government. As early as during the administration of former President Biden, ted cruz was then a Republican senator from Texas and the current chairman of the Senate Science Committee.（Ted Cruz）My office once published a report that from January 2021 to April 2024, 3,483 research funds approved by NSF went to "promoting diversity, fairness and inclusiveness"（DEI）The principle of suspicious projects ",wasted $2 billion.

With the advent of the Trump 2.0 era, in February this year, NSF initiated a review of all funding, with the aim of ensuring that Trump’s executive orders on "radical and wasteful" DEI projects and "gender ideology" were not violated. Among them, there are hundreds of "sensitive words" that are thought to be related to ideology but not to hard science, such as "female", "black" and "inequality".

On April 14th, DOGE turned its attention to NSF funding again. Its staff entered the NSF headquarters building in Alexandria, Virginia, and gained access to its funding management system, and used this access to prevent the disbursement of hundreds of research funds that had been approved in the multi-step review process and only needed to be finalized.

"This makes us feel scared." An NSF project official said.

It is reported that NSF’s research proposal has to go through several steps before it is approved: first, it is submitted to NSF project officials with professional knowledge. If it passes the review, it will entrust a third-party independent expert to review it, and the success rate is usually between 20% and 30%; Next, NSF department heads approve the funds and submit them to the appropriation and agreement department for final approval. However, DOGE’s intervention made the application for funding that had already reached the last step be returned.

It is worth noting that before DOGE was established in January this year, NSF’s new research funding rate has slowed down by half compared with 2024. As of April 16, the relevant funding has completely stopped.

US White House Spokesman Kush Desai（Kush Desai）The explanation given is: "The Trump administration is committed to ensuring that federal research expenditures meet the daily needs of the American people."

However, Democrats in the US House of Representatives believe that Cruz’s report and DOGE’s practice have major defects, which will "undermine the important work of researchers, educators and institutions" and will "endanger the US economy and national security".

According to statistics, at present, more than 200 proposals have been marked as "considering termination" by DOGE. Some of these proposals were marked because they contained wording about the "wider impact" of research on society-wording that Cruz did not like. Anthony Kit, a computational biologist at the University of Wisconsin-Madison（Anthony Gitter）It was "named" by Cruz. Kit said, "Cruz believes that universities are elite gathering places, accommodating scholars who do not engage in scientific research and are out of touch with reality. But his view is out of touch with the actual situation. "

In this regard, Zoe Lofgren, a senior Democrat of the Science, Space and Technology Committee of the US House of Representatives,（Zoe Lofgren）Turaman Panchanatan, director of NSF.（Sethuraman Panchanathan）"NSF must avoid being led by the nose and being forced to accept these empty findings and undermine its own audit procedures," wrote the letter.

Second, the "strangled" science

The Trump administration in the era of 2.0 not only made NSF tremble, but also made life difficult for many national scientific research and funding institutions.

NIH is one of them. As a large national biomedical research funding institution in the United States, its subordinate laboratories also employ thousands of scientists. The biggest dilemma faced by the scientists of this institution is "running out of ammunition and food".

In February this year, the Trump administration set the consumption limit of almost all government credit cards to $1 each, which brought a disastrous blow to NIH’s laboratory-it was impossible to buy gloves, pipettes, Petri dishes, reagents, storage bottles and other basic scientific research materials. For example, a laboratory ran out of chemicals used for cryopreservation and treatment of organ donors’ brains; Another key laboratory lost half of its staff in the wave of layoffs and had to "borrow" staff from other teams to continue the work of analyzing blood samples for more than 200 clinical trials.

"NIH can’t hire people, recruit students, travel and communicate with the outside world at present … It is completely paralyzed and can’t operate normally." A chief researcher of the agency said.

The FDA of the United States was also seriously affected by the layoff plan and was forced to suspend most of its food safety testing. As of April 18, the agency’s work on bird flu testing for milk, cheese and pet food has stopped. The same is true of NOAA. Many probationary employees who have been on the job for less than two years were fired first, then re-employed, and then placed on administrative leave, because their jobs were in jeopardy and people were worried.

Other actions of the Trump administration are also "overweight" the difficulties faced by scientists. NIH researcher strait Fowood(alias Straight Forward)It is said that Trump administration officials will put forward various "wonderful" requirements: such as collecting the list of all contract workers and issuing an ultimatum. If they fail to reply within 24 hours, they will be dismissed. "These endless demands are killing the function of a scientific research institution with red tape." Fowood said.

In addition, the Trump administration has also cut research funding for research projects such as vaccines and climate science, and the upcoming new round of layoffs has aggravated the current turmoil. "Everyone is working hard, but morale is really low." Fowood said.

The EPA has always been the target of the Trump administration, and it is forbidden to track the greenhouse gas emission reduction of clean energy technology projects. Those high-emission enterprises can apply for "presidential exemption" and are no longer bound by pollution regulations. This makes many employees lose confidence. An EPA employee bluntly said: "I like this job very much, but the actions of the federal government make EPA no longer a place where people want to work."

"In the past, the federal science policy was’ not perfect’, but before Trump took office, some reforms might be welcomed. But now, the government is’ destroying everything’ … We are constantly bombarded by a large number of arbitrary administrative instructions. " The aforementioned NIH chief researcher bluntly said.

Third, who wins and loses in the "tug-of-war"

Observers believe that the Trump administration’s new round of cold current of science and technology policy has not yet ended. For example, according to Washington post, the White House’s upcoming draft budget for fiscal year 2026 plans to cut 40% of NIH’s current budget of $47.4 billion, merge the original 27 institutes into eight, and cancel the Institute of Nursing and Minority Health. Therefore, the current American scientific community is still far from welcoming the coldest moment.

Many people believe that Trump’s intervention in the American scientific research system is not a temporary rise, but a continuation of his policy philosophy in the 1.0 era. At that time, Trump called climate change a "scam", repeatedly tried to cut the budgets of EPA and NIH, and appointed Scott Prut who had sued EPA.（Scott Pruitt）As the director.

Today, this kind of intervention is not only continuing, but also a systematic implementation path-"2025 Plan".（Project 2025）.

This plan was released by the Heritage Foundation of the Republican Party in April 2023. It is a 922-page "policy blueprint" aimed at providing detailed policy recommendations for the Trump 2.0 era.

Previously, the policy recommendations in the plan, including banning abortion, reforming the federal government and cutting funds for climate science, had aroused strong public opposition. Trump claimed not to know about the plan during the presidential campaign. However, according to the Wall Street Journal, more than half of Trump’s executive orders are consistent with the recommendations of the "2025 Plan", and most of the 40 authors listed in the plan are key figures in the Trump administration, and six of them are even nominated by Trump as cabinet members.

The "2025 Plan" defines many science-related policies. These include anti-diversification efforts, such as "canceling policies and procedures that promote gender, race and equality initiatives under the banner of science" and "canceling funding for climate science and green energy" on page 60; Cut university funds, such as "Congress should limit the indirect expenses paid to universities" on page 355; Reduce the size of the government, such as "permanently and substantially reduce the number of non-defense federal employees" on page 78.

The analysis of Nature magazine shows that the Trump administration is considering implementing some other suggestions in the "2025 Plan", including prohibiting fetal tissue research and canceling or greatly reducing the number of visas issued to foreign students. The analysis also shows that the Trump administration’s executive orders are not always consistent with the plan, and in many cases, even more extreme practices have been taken than the plan.

These political interventions make the American scientific community uneasy. At the end of March, about 1,900 members of the National Academy of Sciences, the Academy of Engineering and the Medical College from more than 400 universities and research institutions in 38 States issued a joint open letter, pointing out: "At present, the American scientific community is shrouded in an atmosphere of terror … The Trump administration is dealing a heavy blow to the scientific cause of the United States by cutting research funds, dismissing scientists, revoking the public’s access to scientific data, and forcing researchers to change or give up their jobs for ideological reasons."

Some opposition voices have also entered the judicial process. For example, in mid-April, the American Education Research Association and the Education Effect Research Association jointly filed a lawsuit in the Federal District Court of Maryland, demanding the restoration of scientific research funds and personnel allocation. In February this year, the attorneys general of 22 States in the United States filed a joint lawsuit against the Trump administration for cutting research funding in the medical and public health fields.

However, there are also many scientists who take a wait-and-see attitude towards the behavior of the Trump administration. Sasha gusev, a statistical geneticist at the Dana Farber Cancer Institute in Boston.（Sasha Gusev）It is believed that it may also contain reform opportunities, such as the reform of NIH structure and the reflection on the funding process, which will help to improve the efficiency of its capital use and the diversity of recipients. However, he also stressed that the reform should be optimized based on the existing system, rather than completely overthrown. If the strategy of "burning it and rebuilding it" is adopted, NIH, which is regarded as the "global biomedical laurel", may be hit.

Despite the persistent doubts, the Trump administration’s pace of scientific funding cuts and layoffs has not slowed down. Michael Loubere, physicist and researcher of science and technology policy at new york City University.（Michael Lubell）It is believed that the American scientific community is facing an unprecedented "uncertainty tug-of-war": "Some fields will become winners, such as the direction supported by Trump and Musk; However, under the premise of tight federal budget, there are also doomed losers. "

References:

https://www.nature.com/articles/d41586-025-01263-0

https://www.nature.com/articles/d41586-025-01245-2

https://www.nature.com/articles/d41586-025-00052-z

http://www.xinhuanet.com/20250401/b73c352eff4446f3b6ea2acfa5fea05e/c.html

This article comes from WeChat WeChat official account:Science network, Author: Song Shufei, Feng Lifei

Wen | amino observation

In the world of innovative medicine, the most important thing is the story of subversion.

From Baekje Shenzhou to Hengrui Pharma, it became the first innovative medicine, and then to the strong rise of domestic CAR-T and ADC, subversion continued.

In the innovative medicine camp, a group of unscrupulous pharmaceutical companies have even begun to make medicines. This may be subversive.

For example, Bailey Tianheng, which was born at the end of last year, set the world’s largest BD for ADC with a total transaction volume of 83 US dollars. People are surprised that a small imitation pharmaceutical company in Sichuan can also make a unique pipeline in the world?

For another example, Xiangxue Pharmaceutical, which has been popular recently, and the TCR-T therapy TAEST16001 developed by its subsidiary Xiangxue Life Sciences have been included in the list of breakthrough therapeutic varieties, and it is expected to become the first TCR-T listed. Xiangxue Pharmaceutical has also transformed from an old Chinese patent medicine enterprise into a leading company of advanced cell therapy, but the skyrocketing under the hype has come and gone quickly.

There are many incredible people, ideas and technologies in the field of innovative drugs, as well as a lot of hype. Therefore, the sense of separation and subversion is also increasing day by day.

However, the hype belongs to the hype, and the industry belongs to the industry. How is Xiangxue Pharmaceutical made? Behind this, how should we treat "innovation"?

01 innovative drugs are the most subversive.

When innovation becomes the main theme of the industry, transformation has become a top priority for all traditional pharmaceutical companies.

However, the opposition between tradition and innovation, and the gap between imitation and originality, most people think that traditional pharmaceutical companies have fallen behind, and no matter the size of enterprises, including big brother Hengrui Pharma, it is inevitable to ask: how can a generic drug maker make innovative drugs?

In particular, the listing of domestic PD-1 in 2018 and the opening of the two major exchanges to unprofitable biopharmaceutical companies, the whole capital and industry side, together pushed the innovative drug industry to the peak, and the field of innovative drugs was no different for a while, while traditional pharmaceutical companies once became the most desolate existence.

In fact, in the field of innovative drug research and development, traditional pharmaceutical companies have been slow, but it does not mean that they have completely lost opportunities.

Therefore, with the development of time, the transformation of some big pharmaceutical companies, such as Hengrui Pharma, Hansen Pharmaceutical and Unacon, is not smooth sailing, but it is natural because they have money and resources.

Subversion began when Baekje Shenzhou surpassed Hengrui and became the first brother of innovative medicine.

In 2022, the revenue of innovative drugs of the former surpassed that of the latter for the first time. This means that the leader of the domestic innovative drug market has changed hands. The young Baekje Shenzhou is still soaring, and its overall revenue may soon surpass that of Hengrui Pharma.

A number of new biotech faces have also begun to emerge. For example, in the emerging field of small nucleic acid drugs, Bowang Pharmaceutical, established in 2021, reached a cooperation with Novartis with a down payment of 185 million US dollars and a potential transaction of 4.165 billion US dollars to jointly develop a variety of cardiovascular siRNA drugs;

Yilian Bio, established in 2020, has successively reached cooperation with Roche and BioNTech with the story of its new generation ADC.

The research and development achievements of a new generation of biotech began to appear, which was expected by the market, because they were born for innovation.

The real subversion may be that a group of unscrupulous pharmaceutical companies have even begun to make medicines.

There was Bai Li Tian Heng, who was born in 2023. On December 12th, BL-B01D1, a dual-antibody ADC drug developed by Bailey Tianheng, was license out to Bristol-Myers Squibb with a total transaction amount of up to $8.3 billion.

This not only set a down payment record for the domestic innovative drug license out transaction, but also set a new record for the total price of the global ADC single drug transaction.

Who is Bai Li Tian Heng? Prior to this, its label was more "a Sichuan imitation pharmaceutical company".

Later, Xiangxue Pharmaceutical, the leader of A-share new cell therapy, rose by 227.5% in 11 trading days with the first overseas TCR-T therapy listed.

TAEST16001 injection developed by its subsidiary Xiangxue Life Sciences has been included in the list of breakthrough therapeutic varieties, and it is expected to become the first TCR-T cell therapy drug listed in China.

Who is Xiangxue Pharmaceutical? Prior to this, its label was more "anti-infective Chinese patent medicine enterprises". But this time, Xiangxue’s logic has changed, from an old Chinese patent medicine company to a leading company in advanced cell therapy.

Looking back, how did Xiangxue Pharmaceuticals make it?

How are the fragrant snows tempered?

Let’s look at Xiangxue Pharmaceutical first.

As an old Chinese medicine enterprise, it has neither the abundant internal resources of other big pharmaceutical companies nor the financial resources bought by buy buy willfully. How did a company relying on Chinese herbal medicines and oral liquid win the first domestic TCR-T therapy crown?

The story will start in 2012. At that time, Li Yi, a big cow in the field of cellular immunotherapy, returned to China to join the Guangzhou Institute of Biomedicine and Health of the Chinese Academy of Sciences and established a research platform, but he still needed to find a company to land.

When Li Yi worked in Avidex founded by Oxford University, he invented the guided evolution technology of TCR and used it to isolate and optimize the world’s first human-derived soluble TCR with high affinity, which opened the way for TCR to move from scientific research to clinical practice. Thanks to this key technological breakthrough, Immuncore, the leading company of TCR-T, has gradually developed from an early biotechnology company hatched by Oxford University to a company with multiple clinical products.

After returning home, by chance, Li Yi met Wang Yonghui, chairman of Xiangxue Pharmaceutical, and the two agreed to set up a life science research center and jointly establish a laboratory within Xiangxue Pharmaceutical.

Since 2013, Xiangxue Pharmaceutical has recruited scientists headed by Li Yi and Gong Haiping, which led to Xiangxue Life Science, which later became TCR-T.

In external reports, Xiangxue Pharmaceutical paid a price of 180 million yuan in five years for the promotion of TCR-T project. Among them, TAEST16001 has made the fastest progress. According to the wall newspaper data presented at this year’s ASCO meeting, as of April 2024, eight subjects were selected into the phase II clinical trial of TAEST16001, with the best remission rate of 50% and the median progression-free survival (mPFS) of 5.9 months.

From an industry perspective, the leading TCR-T company Immunocore, Adaptimmune, which just promoted the world’s first TCR-T therapy to be listed at the beginning of the month, and Xiangxue Life Sciences, the research and development teams of these three companies were actually one more than 10 years ago, that is, Avidex, where Li Yi worked.

From this point of view, several TCR-T products that are currently in the front line are only a few technologies transformed from the academic circles at that time, and they have landed in different countries and enterprises at the same time.

TCR-T is similar to CAR-T in mechanism. Compared with CAR-T, TCR is more similar to natural T cells in human body (CAR is only a fragment), which is not only safer, but also transmits stimulation signals to cells through TCR-CD3 complex. Therefore, TCR-T can not only identify antigens on tumor surface, but also identify antigens inside tumor. Therefore, TCR-T is more suitable for the treatment of solid tumors.

Even if it is a promising field, it needs practical results to prove its value. CAR-T therapy is widely known, largely thanks to successful cases like Emily’s, and then a variety of products have been listed one after another, opening a new era of cell therapy.

Although TCR-T therapy has great potential in theory, there is no product that really stands firm in the market.

Back to 12 years ago, not many companies were willing to spend hundreds of millions of dollars and continue to transfuse blood every year to bet on a track with uncertain future. Xiangxue has paid a lot for this. At present, the debt ratio of the company exceeds 70%, which is much higher than that of its peers such as Jichuan Pharmaceutical, which is about 20%.

Let’s look at Bai Li Tian Heng again.

Its development history can be traced back to 1996, when it started as a generic drug. At that time, Baili Tianheng’s predecessor, Baili Pharmaceutical, was established. Under the leadership of its founder, Yi Zhu, it launched the first generic drug, ribavirin granules, which once became a big single product.

Yi Zhu’s career is also "unusual". He majored in radio science, and later he got a master’s degree in biophysics from Fudan University and a doctor’s degree in corporate finance from Sichuan University. I have done real estate, set up Baili Pharmaceutical, and after taking the generic route, I took the sales team to fight in the front line.

Under the influence of drug quantity procurement and consistency evaluation, the company’s generic drug business revenue has been declining year by year, and the losses have been increasing. No one will believe that such a generic pharmaceutical company will make a name for itself in the field of innovative drugs. So, after the announcement of its deal with BMS, some people asked, who is Bailey Tianheng?

As early as 2008, Yi Zhu began to dabble in innovative drugs. Regrettably, after several years of tossing, many projects all failed.

However, he did not give up making innovative drugs. In 2014, he established an innovative pharmaceutical company in Seattle, Systimune. Ltd, which focused on the research and development of tumor drugs, and set up a research and development team.

At that time, Yi Zhu wrote a manuscript of the company’s plan for the next ten years: double antibodies, multi-antibodies and ADC drugs. At that time, the listing of TDM1 did not attract the attention of the industry. ADC drugs were at a low point in the United States, but he proposed to do double-antibody ADC.

It is believed that the toxicity problem of monoclonal antibody ADC has not been solved for the time being, and the uncertainty of dual antibody ADC will only be higher. However, Yi Zhu believes that technical problems can be solved, and it only takes time and investment: if there is a risk, strengthen the risk tolerance; If the resources are not enough, then think about how to get them back.

In June, 2023, Bailey Tianheng reported the first human clinical phase I research data of BL-B01D1 at ASCO meeting. BL-B01D1, which was not optimistic in 2014, was developed by Bailey Tianheng.

The results showed that the overall ORR was 45.3% when the median follow-up was 4.1 months, including 63.2% for EGFR mutant NSCLC, 44.9% for EGFR wild-type NSCLC and 53.6% for NPC patients.

It is such data that has contributed to its cooperation with BMS.

03 Tear off the "label"

In the eyes of the market, there may be only one truly smooth path for the transformation of generic pharmaceutical companies in China.

That is, to become a giant, after having a lot of resources, to acquire an already formed innovative drug system, or license in real innovative drugs, but most generic pharmaceutical companies are not enough.

The biggest argument for questioning the transformation of small-scale traditional pharmaceutical companies is that the development of new drugs abroad takes ten years and costs one billion dollars. A generic pharmaceutical company has a profit of only tens of millions of RMB a year. Why should it be a truly innovative drug?

Objectively speaking, such doubts are reasonable and normal. But it is this solidified way of thinking that increases the sense of separation and subversion in the field of innovative drugs.

For example, no matter Xiangxue Pharmaceutical or Baili Tianheng, we can see that the unscrupulous pharmaceutical companies can actually make innovative drugs.

Undeniably, there is a wave of speculation based on expectations behind Xiangxue Pharmaceutical’s stock price surge, and the clinical results are still unknown, and the skyrocketing speculation has come and gone quickly. In fact, its clinical data has also been questioned by some insiders, such as why the sample size is so small? How are 8 patients screened? Can you reproduce the same eye-catching data under the premise of increasing the number of overseas samples?

Everything has yet to be verified by time.

After the release of clinical data, Baili Tianheng was also questioned. When it reached a cooperation with BMS, it was regarded as a "dark horse" in the field of innovative drugs in China. It is also a medicine. After being endorsed by big pharmaceutical companies, the attitude of the market has changed rapidly.

Behind this, more is the role of "labels". Instead of directly judging the value of the drug itself, it is better to see who made it, who invested it and who bought it. Based on such a "label", it is easier to draw new and recognized conclusions.

Although it is important who made it and who bought it, even top researchers can’t violate the objective laws of the industry; Top multinational pharmaceutical companies can’t guarantee the success rate of every project and every transaction.

Perhaps, it is time for us to "label" thinking and treat "innovation" correctly.

In all fields, many times, things that others think can’t be done are not necessarily as difficult as they think. Just like the athletes who broke the monopoly of Europeans and Americans in this year’s Olympic Games, Pan Zhanle in swimming and queen Zheng Qinwen in tennis.

The same applies to the field of innovative drugs. There is no taking it for granted, and there is no impossibility. It is more a combination of necessity and accident.

Returning to the logic of innovative drug research and development, the achievements presented by Xiangxue Pharmaceutical and Baili Tianheng are, in essence, more a result of the innovative layout started 10 years ago; The key factor that determines how they will be three or five years later is the current layout and investment.

No matter whether it is biotech or traditional large pharmaceutical companies or small pharmaceutical companies, no one can succeed casually. It needs money, people and strategies, but also needs to advance and persist. What’s more, innovation is a divergent competition.

There is no absolute center for drug research and development, and the core depends on the efficacy of the product. The curative effect is determined by different principles and technical routes, and no one can monopolize and preset the results.

Because there is no fixed number of medicines.

　　At today’s "1+1" series press conference on "Ten Years of Education", the Department of Science, Technology and Information Technology of the Ministry of Education said that since the 18th National Congress of the Communist Party of China, the Ministry of Education has successively issued and implemented the 12th Five-Year Plan for the development of science and technology in institutions of higher learning, and organized and implemented a number of major actions such as the plan for improving innovation ability, the independent innovation action in key areas and the plan for basic research on Mount Everest. The ability of scientific and technological innovation in colleges and universities has been greatly improved, the reform of system and mechanism has been continuously deepened, and remarkable results have been achieved in serving the major needs of the country, which has made irreplaceable and important contributions to the construction of an innovative country and a powerful country in education and science and technology.

　　The ranks of scientific and technological talents have grown stronger.. In the past ten years, the group of strategic scientists and leading talents in colleges and universities has grown steadily. More than 40% academicians of the two academies and nearly 70% winners of the National Science Fund for Distinguished Young Scholars have gathered in colleges and universities. Cultivating high-quality innovative talents through high-level scientific research has supported the training of millions of master’s and doctoral students.

　　Scientific and technological innovation resourcesspeed upassemble.In the past ten years, the R&D (research and development) funds in colleges and universities have increased from 76.87 billion yuan in 2012 to 159.2 billion yuan in 2021, and the total amount of funds allocated in the past ten years has reached trillions. The funds entrusted by enterprises and institutions increased from 39.18 billion yuan in 2012 to 84.75 billion yuan in 2021, an increase of over 116%. The full-time equivalent of R&D personnel in scientific and technological activities in colleges and universities has increased from 209,000 person-years in 2012 to 334,000 person-years in 2021, an increase of nearly 60%.

　　The innovation platform system is more perfect.In the past ten years, universities have taken the lead in building more than 60% of the state key laboratories of disciplines and 30% of the national engineering (technology) research centers; Aiming at the forefront of science and technology in the world and the major needs of the country, the Ministry of Education has actively laid out and built 25 frontier science centers, 14 platforms for tackling key problems in key areas, 38 national-level collaborative innovation centers, and more than 1,500 platforms such as key laboratories of the Ministry of Education, engineering research centers and collaborative innovation centers jointly built by provinces and ministries.

　　The contribution of scientific and technological innovation is more significant.In the past ten years, colleges and universities have won 6 out of all 10 national natural science first prizes, accounting for 67% of all natural science prizes, and have won the national natural science first prizes in recent three years, which is a veritable main force in basic research. In the past ten years, colleges and universities have won 10 of all 11 first prizes for national technological inventions, 72% of all technological inventions, and two special prizes for national scientific and technological progress, becoming the source of major scientific and technological breakthroughs.

　　The ability to transform results has been significantly improved.In the past ten years, the number of patents granted in colleges and universities has increased from 69,000 to 308,000, an increase of 346.4%, and the authorization rate has increased from 65.1% to 83.9%. The number of patent transfer and licensing contracts has increased from more than 2,000 to 15,000, and the amount of patent conversion has increased from 820 million yuan to 8.89 billion yuan, an increase of nearly 10 times, which has not only achieved quantitative growth, but also achieved qualitative improvement, transforming more scientific and technological achievements into real productive forces.

　　International scientific and technological cooperation is more extensive.. In the past ten years, colleges and universities have sent nearly 400,000 people to participate in international scientific and technological cooperation research, attended 1.74 million international academic conferences, published 187,000 specially invited reports and exchanged 883,000 papers. Colleges and universities have extensively carried out in-depth international cooperation with foreign high-level universities and research institutions, and built more than 70 joint laboratories for international cooperation, which has become an important window and bridge for international scientific and technological cooperation.

　　(CCTV reporter Xue Chen Zhao Yingchen)

On October 28, 2024, it was officially listed, and four models were launched, with the price range of 24,900 yuan to 39,900 yuan. At this conference, Pentium Pony cooperated with the well-known IP "Pony Baoli" for the first time, which attracted many women and children to participate in the interaction. This cross-border joint name is not only the first cooperation between Xiaoma Baoli and a car company, but also the first video joint name, which further enhances the attraction of the event.

The four models launched this time are: 122km cute horse, priced at 24,900 yuan; 170km energetic horse, priced at 31,900 yuan; 222km smart horse, priced at 36,900 yuan; And 222km lightning horse, priced at 39,900 yuan. In addition, Pentium Pony also announced a series of preferential policies for car purchase to attract more consumers.

Pony Baoli is a well-known IP for girls launched by Hasbro Company in 1980s. Its core concept revolves around dreams, creativity, kindness, courage and self-confidence. These images are highly compatible with the brand positioning of Pentium Pony. Pentium pony used many capsule lines in its design, incorporating the front and rear bumpers, the contrasting decorative parts of the side doors and the interior details. This design is inspired by the capsule car in the famous animation, and the Pentium pony shows the childhood dream in its unique way.

In terms of design, the Pentium pony abandoned the traditional square box design and adopted streamlined elements. The body size was 3000mm x 1510mm x 1630mm, and the overall shape was round and full, with smooth curves. The front face was designed with a contrast grille, which made it more lovely and attractive. In terms of interior, this new car adopts a "dessert"-like color scheme, and the layout of the shift knob is designed on the dashboard, so the user does not need to bow his head when operating, which is convenient and safe. At the same time, the brake pedal and the switch pedal are designed with music "pause" symbol and game "acceleration" symbol respectively, which adds interest.

In terms of battery life and performance, Pentium Pony also performed well, providing the longest battery life of 222km in its class, and upgrading the fast charging function, which can increase the battery life by 100km after charging for 1 hour. It is equipped with a 30kW high-power motor, which has stronger power performance and more flexible starting to meet the needs of daily travel.

Since its listing in May this year, Pentium Pony has continued to sell well, with sales exceeding 10,000 units in September, which is widely loved by trendy moms, fashionable women and families with children. With the price close to the people and relatively low maintenance cost, Pentium pony has become an ideal means of transportation for daily short-distance travel. If you are considering a scooter, Pentium Pony is undoubtedly a worthy choice.

　　Guangzhou Daily News (all-media reporter Ren Shanshan correspondent Yu Guangbiao) The hoarse voice has not improved for more than a month, not necessarily "getting angry", but more likely laryngeal cancer! If you smoke for a long time, you should be more alert to the risk of laryngeal cancer.

　　Recently, the first member congress of the professional committee of laryngopharyngeal cancer of Guangdong Clinical Medical Association and the second standardized diagnosis, treatment and new progress course of laryngeal and laryngopharyngeal cancer were held in Guangzhou. Professor Liu Xuekui, Chairman of the Professional Committee of Laryngolaryngeal Tumors of Guangdong Clinical Medical Association and Head and Neck Surgery of Cancer Prevention Center of Sun Yat-sen University, pointed out that in recent years, the incidence of laryngeal cancer has shown an increasing trend, ranking second among all head and neck tumors, and the incidence has shown a younger trend. He reminded that men who have a history of smoking and are over 40 years old should see a doctor as soon as possible and have an electronic laryngoscope examination once they have hoarseness for more than a month frequently, or if the heat-clearing and anti-inflammatory treatment according to pharyngitis does not work.

　　Liu Xuekui pointed out that the 5-year survival rate of early treatment of laryngeal cancer can reach more than 90%, and once it is diagnosed in the advanced stage, the survival rate will drop sharply. "Like many cancers, in China, when many patients with laryngeal cancer are diagnosed, they often reach the middle and late stage, and the treatment of advanced laryngeal cancer is still a problem." He reminded that patients with suspicious symptoms of laryngeal cancer should be examined by electronic laryngoscope. The examination cost of electronic laryngoscope is not high, and it is very convenient. Once you see a suspicious tumor in the throat, the doctor takes a sample for pathological examination, which is conducive to the early diagnosis.

　　At present, the clinical treatment methods for laryngeal cancer mainly include radiotherapy, surgical treatment, comprehensive treatment of radiotherapy and surgery. Generally speaking, the treatment of early laryngeal cancer is mainly surgery and radiotherapy, and comprehensive treatment is needed in the middle and late stage.

　　The traditional treatment mode of locally advanced laryngeal cancer is total laryngectomy plus postoperative radiotherapy, and the lesion is completely removed. The survival situation of patients is still optimistic. However, under this treatment mode, the function of larynx is often seriously damaged or even unable to be preserved, which affects the respiratory function and vocal function of patients and leads to poor quality of life.

　　In recent years, with the medical profession paying more and more attention to the quality of life of cancer patients, some doctors have proposed that the laryngeal function should be preserved as much as possible in the treatment of advanced laryngeal cancer, and radiotherapy and chemotherapy should be carried out first, and then surgical resection should be carried out if the effect is not good or the disease recurs.

　　Liu Xuekui pointed out that it is important to preserve laryngeal function, but it is more important to save the patient’s life first. Clinical practice shows that radiotherapy and chemotherapy are difficult to achieve good results in a considerable number of patients with laryngeal cancer. Under the treatment idea of "preserving function first", patients may miss the best opportunity for surgical resection and eventually fail to operate. "It is equivalent to that if the scheme of radiotherapy first and then surgery is not effective, the previous radiotherapy and chemotherapy will be wasted, and the radiotherapy and chemotherapy after surgery will be ‘ Remedy ’ The opportunity is also lost. " He believes that when deciding the treatment plan, doctors need to make careful choices, depending on the specific situation of patients.

　　It is worth mentioning that in recent years, Liu Xuekui innovatively used titanium mesh stent to reconstruct laryngeal function, which provided another safer, more reliable and economical treatment method for patients and brought good news to patients. At present, this new technology has won the national invention patent and has been adopted by many hospitals in China.

　　Cctv newsAccording to official website, Beijing Administration of Traditional Chinese Medicine, at present, Beijing is in an influenza epidemic period, in which influenza A (H1N1) virus predominates and co-prevails with influenza A (H3N2) virus. The number of fever clinics in some medical institutions continues to increase, especially in pediatrics. In order to ensure the people’s demand for medical treatment and give full play to the characteristics and functions of traditional Chinese medicine scientifically, effectively, safely and steadily, the Beijing Municipal Administration of Traditional Chinese Medicine organized the Beijing Expert Group on Prevention and Treatment of Influenza with Traditional Chinese Medicine to formulate the Chinese Medicine Prevention and Treatment Plan for Spring Influenza in Beijing in 2023 (Trial).

　　The Beijing Municipal Administration of Traditional Chinese Medicine said that the health departments of all districts should organize experts to strengthen the guidance on the use of Chinese patent medicines, hospital preparations and Chinese medicinal decoction, especially referring to the catalogue of Chinese patent medicines attached to the prevention and control plan of Chinese medicine, and strengthen the publicity and guidance for patients, and guide patients to scientifically choose various Chinese medicinal preparations such as Chinese medicinal decoction and Chinese medicinal formula granules and substitute western medicine, Chinese patent medicines, hospital preparations and Chinese medicinal decoction. At the same time, the local medical institutions are urged to reserve and allocate relevant Chinese patent medicines and Chinese herbal pieces.

　　Beijing will strengthen the pediatric diagnosis and treatment services of traditional Chinese medicine, encourage qualified Chinese medicine medical institutions to open all pediatric clinics, and coordinate medical resources without excessively increasing the burden on medical staff, and open pediatric delayed clinics and night clinics to meet the medical needs in the peak period of epidemic. Encourage Chinese medical institutions (including Internet hospitals and medical institutions providing Internet diagnosis and treatment services) to prescribe online for influenza patients through the Internet diagnosis and treatment platform, and entrust qualified third parties to deliver medicines to patients’ homes. Encourage medical institutions to provide 24-hour online consultation services, and provide medical consultation, medication guidance and other services for influenza patients.

Recommended Catalogue of Chinese Patent Medicines Related to Influenza Treatment in Spring of 2023

Chinese Medicine Prevention and Treatment Scheme for Spring Influenza in Beijing in 2023 (Trial)

　　First, children’s influenza treatment prescription

　　【 Clinical manifestations 】 Acute onset, high fever, anhidrosis, body pain, sore throat, runny nose, cough, anorexia, nausea and vomiting, and dry stool. Red tongue, thick white or yellow fur, and floating pulse. The cough lingers after the fever has gone down.

　　1. Lung Wei Feng fever

　　[Treatment] Dispelling weathering and dampness, clearing away heat and toxic materials

　　[Basic Party]

　　Yinhua 10g Lianqiao 10g Huangqin 10g Cangshu 6g

　　Gypsum Fibrosum 15g (decocted first), Rhizoma Phragmitis 15g, Herba Agastaches 10g (later) and Fructus Arctii 6g.

　　Thin lotus 5g (bottom) Chenpi 6g raw malt 9g

　　One dose a day, decoction or granules, taken orally after meals: 3-6 years old, 50ml each time, twice a day; 6-14 years old, 100ml each time, twice a day; 14-18 years old, 200ml each time, twice a day.

　　[Chinese patent medicine] Children’s Ganmao Granules, Children’s Chiqiao Qingre Granules, Jinlian Qingre Effervescent Tablets, Qinxiang Qingjie Oral Liquid, Children’s Chaigui Antipyretic Granules, Children’s Resuqing Granules, etc.

　　2. Phlegm blocks the lung.

　　[Treatment] Dispelling lung heat, relieving cough and resolving phlegm

　　[Basic Party]

　　Roasted ephedra 3g bitter almond 6g gypsum 15g (fried first) orange stalk 3g.

　　Huangqin 6g Qianhu 10g Lianqiao 10g Gualou 10g

　　Fritillaria thunbergii 6g Houttuynia 10g (lower back) raw licorice 3g radish seed 9g

　　The decoction method is the same as above.

　　[Chinese patent medicine] Children’s cough liquid, children’s Xiaoji Zhike oral liquid, Feire Kechuan oral liquid, children’s Kechuanling oral liquid, Kaihoujian spray, Jinzhen oral liquid and so on can be selected based on syndrome differentiation.

　　Second, children’s influenza prevention prescriptions

　　Folium Isatidis 3g thin lotus 3g fried hawthorn 3g chrysanthemum 3g.

　　Chenpi 6g reed root 10g　　　

　　Decoct with water, one dose per day for 5 days.

　　Third, adult influenza treatment prescription

　　1. Wind-heat attack on table

　　【 Clinical manifestations 】 Fever or no fever, cough, red eyes, dry throat, sore throat, runny nose, thirst, red tongue with thin yellow coating and rapid pulse.

　　[Treatment] Dispelling wind and clearing heat

　　[Basic Party]

　　Silver flower 15g upturned 15g burdock 15g Schizonepeta spike 9g

　　Thin lotus 6g (lower back), mulberry leaf 15g, chrysanthemum flower 15g and Scrophularia 15g

　　Bitter almond 10g Fritillaria thunbergii 10g reed root 30g raw licorice 6g

　　Decoct with water, one dose a day.

　　[Chinese patent medicine] Jinhua Qinggan Granule, Sangju Ganmao Tablet

　　2. Wind-cold bundle table

　　【 Clinical manifestations 】 aversion to cold, fever, head and body pain, cough, white phlegm, thin and white tongue coating and tight pulse.

　　[Treatment] Dispel wind and cold

　　[Basic Party]

　　Baked ephedra 6g bitter almond 10g cassia twig 10g kudzu root 15g

　　Qiang Huo 10g Su Ye 10g (lower back) Jing Jie 10g Bai Zhi 10g

　　Radix Glycyrrhizae preparata 6g

　　Decoct with water, one dose a day.

　　[Chinese patent medicine] Ganmao Qingre Granule, Jiuwei Qianghuo Pill

　　3. Wind-heat invading the lungs

　　【 Clinical manifestations 】 High fever, red throat and sore throat, red eyes and eyelids, thirst and thirst, cough, red tongue with yellow coating, and slippery pulse.

　　[Treatment] Clearing away heat and toxic materials, dispersing lung qi and removing pathogenic factors.

　　[Basic Party]

　　Roasted ephedra 6g bitter almond 9g gypsum 30g (fried first) Zhimu 10g

　　Reed root 30g burdock 15g Fritillaria thunbergii 10g Huangqin 10g　

　　Lonicera japonica Thunb. 15g Artemisia sphaerocephala Thunb. 10g Radix Glycyrrhizae 6g.

　　Glehnia littoralis 15g

　　Decoct with water, one dose a day.

　　　　　　 [Chinese patent medicine] Jinhua Qinggan Granule, Lianhua Qingwen Capsule

　　4. exterior cold and interior heat

　　【 Clinical manifestations 】 aversion to cold, high fever, headache, body aches, sore throat, red throat, stuffy nose and runny nose, thirst, red tongue, thin coating and rapid pulse.

　　Treating exterior syndrome and clearing interior syndrome

　　[Basic Party]

　　Roasted Ephedra 6g Cinnamomum cassia twig 10g Qiang Huo 10g Gypsum Fibrosum 30g (fried first)

　　Huangqin 15g Zhimu 10g Chishao 15g Roasted Glycyrrhiza 6g

　　Decoct with water, one dose a day.

　　[Chinese patent medicine] Jinhua Qinggan Granule, Lianhua Qingwen Capsule

　　5. Pathogenic accumulation in lung and stomach

　　【 Clinical manifestations 】 Fever, aversion to cold, nausea, vomiting, abdominal distension, abdominal pain and diarrhea, and head and body aches. The tongue is red, thick and greasy with fur, and the pulse is slippery.

　　[Treatment] Clearing lung and stomach, eliminating dampness and harmonizing middle energizer.

　　[Basic Party]

　　Pueraria lobata 15g Huangqin 15g Huanglian 10g Cangshu 15g

　　Huoxiang 10g (bottom) Jiang Banxia 9g perilla 10g thick plain 10g.

　　Bitter almond 9g white peony 12g licorice 6g

　　Decoct with water, one dose a day.

　　[Chinese patent medicine] Gegen Qinlian micro pill, Huoxiang Zhengqi preparation, etc.

　　6. Poisonous gas camp

　　【 Clinical manifestations 】 High fever, cough, chest tightness, shortness of breath, dysphoria, even delirium, obstructed stool, crimson tongue, yellow fur and rapid pulse.

　　[Treatment] Clearing qi, cooling camp, dredging fu organs and inducing resuscitation.

　　[Basic Party]

　　Roasted Ephedra 9g Bitter Almond 9g Gualou 30g Raw Rhubarb 10g (lower back)

　　Gypsum 45g (fried first), red peony 15g, buffalo horn 30g and silver flower 15g

　　Lianqiao 15g Ginseng 15g (decocted separately) Zhimu 10g

　　Decoct with water, one dose a day.

　　[Chinese patent medicine] Angong Niuhuang Pill, Tanreqing, Xuebijing, Qingkailing, Xingnaojing injection, etc.

　　Fourth, adult influenza prevention

　　1. Trollius 3g, mint 3g, raw licorice 3g, instead of tea.

　　2. Those who are susceptible to cold can use ginger 10g and jujube 5g instead of tea.

　　V. Nursing care

　　1. Pay attention to climate change and increase or decrease clothes at any time.

　　2. Try to go to places where people gather as little as possible, wear masks, ventilate the room and wash your hands frequently.

　　3. Drink more warm water after suffering from the flu, have a light diet and keep the stool unobstructed.

　　4. The elderly, pregnant women, infants, obese people and people with chronic diseases should seek medical advice immediately after suffering from influenza.Under the guidance of a doctor, choose Chinese medicine for syndrome differentiation and treatment..

Kiritani mirei, Shohei Miura.

1905 movie network news According to Japanese media reports, kiritani mirei’s love affair with Shohei Miura was exposed. In 2016, the two performed the Japanese drama "People Who Like". In the play, kiritani mirei’s heroine, Miyuki Sakurai, has always had a crush on Shohei Miura’s Saizaki Chihiro, but they are not together in the end. Off-stage, the two leading actors finally got married.

In early December, kiritani mirei was photographed shopping in the supermarket near the apartment.

It is reported that kiritani mirei and Shohei Miura have recently started to associate, and they still live in the same apartment building and are neighbors. According to informed sources, the two have known each other for more than five years. At the time of filming "Someone You Like", Shohei Miura was in contact with actress Honda Tsubasa, but at that time they were already close friends at dinner. In the spring of 2017, after Shohei Miura and Honda Tsubasa broke up, the relationship with kiritani mirei, who had a good talk, warmed up.

Big S, Vic Zhou in and out of the play

Kiritani mirei wasn’t the only one who fell in love with Male No.2 outside the play.In 2001, Meteor Garden became an epoch-making classic in Taiwan Province’s idol drama. However, instead of having a love affair with Jerry Yan, Doumyouji Tsukasa, Big S started a sister-in-law relationship with Vic Zhou, the male No.2 in the drama.

Tang Yan and Luo Jin are in and out of the play.

Coincidentally, in the TV series, Tang Yan, who plays the heroine Mi Duo, is also a real lover with Luo Jin, who plays the spare tire man No.2 Lei Yiming.

　　Recently, the General Secretary of the Supreme Leader made important instructions at the opening of the training course for young and middle-aged cadres of the Central Party School (National School of Administration) in the spring semester of 2024, stressing that on the new journey, young cadres should shoulder heavy responsibilities and have great potential, and they must keep in mind their initial mission, work hard and forge ahead, and strive to run the baton of history. When young cadres are born in great times, they should keep in mind the entrustment, make learning a belief, put the people in their hearts, shoulder their responsibilities, strengthen their confidence, work hard and forge ahead, and constantly contribute to writing a new chapter in Chinese modernization.

　　Make unremitting efforts to strengthen the "accuracy" of theoretical study."Mastering the depth of Marxist theory determines the degree of political sensitivity, the breadth of thinking vision and the height of ideological realm". This is a summary of historical experience and the crystallization of our party’s practice. Young cadres should always take the study of Marxist theory, especially the party’s innovative theory in the new era, grasp it in their hands, put it in their hearts, and implement it in action. With the attitude of "learning without being tired" and "learning from the old", they should insist on reading the original text and understanding the principle, insisting on systematic study of normality, building a solid foundation of faith, supplementing the calcium of spirit and stabilizing the rudder of thought in deep learning and understanding, In the process of observing carefully, doing deeply and doing practically, we can achieve the integration of learning, thinking and practice, and unify knowledge, belief and practice, and truly transform the Supreme Leader’s Socialism with Chinese characteristics Thought in the new era into a powerful force to strengthen ideals, temper party spirit, guide practice and promote work, and continuously inject the "spiritual kinetic energy" of performing duties and responsibilities.

　　Unswervingly, improve the "saturation" for the benefit of the people."Jiangshan is the people, the people are Jiangshan, fighting Jiangshan, guarding Jiangshan, and guarding the hearts of the people." From Lei Feng, who serves the people wholeheartedly, to Jiao Yulu, the "model of the county party secretary", and to Chuanxi Wang, the "leader" in the overall revitalization of the countryside, they all embody deep feelings for the people. "Governing the country is regular and benefiting the people." Young cadres should consciously be selfless devotees who are determined to benefit the people, always put the people in the highest position in their hearts, thoroughly practice the "four basic units", make efforts to solve the "urgent difficulties and worries", solidly promote common prosperity, think more about the people’s livelihood, find more ways for people’s livelihood, and produce more fruits of people’s livelihood, earnestly follow the party’s mass line in the new era, strive to improve their ability to do mass work, and steadily improve the level of people’s livelihood security in development, with visible and tangible use.

　　笃行不怠，跑出实干担当“加速度”。星光不问赶路人，历史属于奋斗者。从石库门到天安门，从小小红船到巍巍巨轮……党和人民事业取得的一切成就，是一代又一代中国共产党人同中国人民接续奋斗的结果。新时代推进强国建设、民族复兴伟业，同样也将在继往开来、接续奋斗中阔步前行。年轻干部要自觉做勇于担当作为的不懈奋斗者，始终胸怀“国之大者”，紧紧围绕新时代新征程党的中心任务，把自己摆进去、把职责摆进去、把工作摆进去，拿出“莫向光阴惰寸功”的拼劲、“坐断板凳熬尽油”的毅力、“踏平坎坷成大道”的豪迈，一件接着一件干，一锤接着一锤敲，在直面问题、解决问题、破解难题中不断打开工作新局面，努力创造无愧于党、无愧于人民、无愧于时代的新业绩。（作者：陈占强）

　　The reference news network reported on July 7. The US media said that the Federal Reserve said on the 5th that the uncertainty of the economic outlook has increased in recent months, but it pointed out that the fundamentals of the US economy are still relatively stable.

　　According to the website of The Wall Street Journal reported on July 5, the Federal Reserve said in its semi-annual report to the US Congress that after 10 years of continuous expansion, the US economy is still stable. However, the report reiterates the recent warnings of policymakers that trade policies, global growth slowdown and other issues pose increasing risks to the economic outlook.

　　The Fed said: "Since the beginning of May, the new news about economic activities has generally become somewhat pessimistic, and the uncertainty of the economic outlook has increased."

　　According to the report, officials "will take appropriate measures to maintain the expansion momentum".

　　The report also said that although the financial system is still "more resilient" than before the 2008 financial crisis, concerns about high-risk commercial loans have intensified.

　　The Fed said: "There are signs that the credit standards of new leveraged loans are not solid enough and have further deteriorated in the past six months."

　　The Fed also said that rising borrowing costs or slowing economic growth may pose "noteworthy risks" to these companies and their creditors.

　　The report said: "Such a development may increase the downside risks of economic activities."

　　According to the plan, Federal Reserve Chairman Powell will submit this report and testify in Congress on the 10th and 11th.

　　The latest economic forecast released by the Federal Reserve on June 19th shows that most policymakers expect the unemployment rate in the United States to stabilize at around 3.6% before the end of this year. It is estimated that the US economy will grow by 2.1% in 2019, while the inflation rate will remain at 1.5%.

　　The forecast shows that among the 17 officials who made predictions before the June meeting, 8 said they expected to cut interest rates this year.

　　The report shows that the "unusual price drop" probably led to the recent low inflation data. The report also reiterated the view of policy makers that this phenomenon may be "temporary".

　　The futures market believes that the possibility of the Fed cutting interest rates at the upcoming meeting is close to 100%. Most central bank officials refused to recognize or refute this possibility in their recent statements. Some officials said they hope to see more data about economic performance in the next few weeks before making a decision.

　　Recently, as American and Chinese leaders reached an agreement on resuming trade negotiations, one of the biggest sources of uncertainty — — US-China Trade Disputes — — The prospects have improved.

　　According to the monthly employment report released by the US Department of Labor on the 5th, following the weak employment data in May, the US economy added 224,000 jobs last month. The Fed report also pointed out that the labor market is still a bright spot in the economic outlook.

　　In recent weeks, some policymakers have been worried that interest rate cuts at this stage may increase the risk of financial imbalances in high-risk corporate debt markets and other fields.

　　According to a report on the website of The New York Times on July 5, Fed officials are worried that the uncertainty caused by the US-China trade war may curb corporate spending, and may lead to a slowdown in manufacturing production and drag down economic growth.

　　The semi-annual monetary policy report issued by the Federal Reserve raised these concerns. According to the report, the current US financial system is more resilient than before the 2008 financial crisis. In the first half of this year, economic activities grew "steadily" and the job market performed well. However, the report also points out the risk that the trade dispute between the United States and China will gradually emerge as it drags on for a long time.

　　The Fed said that the latest round of tariff increase "seems to reduce the import and export of the United States and other countries, and the uncertainty of trade policy may lead enterprises to postpone investment decisions and reduce capital expenditures".